RXi Pharmaceuticals (RXII) Applies to List on the NASDAQ Stock Exchange
Published Monday, July 22, 2013 by Justin Kuepper
RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company focused on developing innovative therapies based on RNA-targeted technologies, has made a lot of progress on the clinical side reporting positive data in its second Phase I clinical trial of RXI-109. With Phase II clinical trials now on the docket, investors in RNA stocks like Alnylam Pharmaceuticals Inc. (NASDAQ: ALNY) and ISIS Pharmaceuticals Inc. (NASDAQ: ISIS) are starting to take notice.

Management has also been focused on the financial end of the business; with a recent CEO interview by Griffin Securities helping build awareness, and recently up-listing to the OTCQX, the company announced today that it would also apply for listing onto the NASDAQ exchange. The move could help improve liquidity in its stock, as well as open up investment to institutions that are normally forbidden from investing in OTC-traded securities.

Read more about the NASDAQ application in the press release below:

RXi Pharmaceuticals Corporation (RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it has filed an application for listing on The NASDAQ Capital Market.

In addition to the application for listing on The NASDAQ Capital Market, RXi today announced a 1-for-30 reverse split of its issued and outstanding shares of common stock. Trading will begin on a post-split basis at the open of the OTCQX on July 24, 2013 under new CUSIP number 74979C303. No fractional shares of common stock will be issued as a result of the reverse stock split and instead holders will receive cash in lieu of fractional shares to which they would otherwise be entitled.

"This reverse stock split combined with a possible NASDAQ Capital Market Listing is the next important step for RXi Pharmaceuticals in becoming a strong biotechnology company," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. He added that ''If approved, we believe that the NASDAQ listing and the reverse stock split will create the conditions for RXi to gain access to a broader institutional investment community, to strengthen our financing flexibility, and to provide greater liquidity for our shareholders."

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (RXII) is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, self-delivering RNAi platform. Therapeutics that use RNA interference, or "RNAi," have great  promise because of their ability to down-regulate, the expression of a specific gene that may be over-expressed in a disease condition. Building on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, a member of the RXi Scientific Advisory Board, RXi's first RNAi product candidate, RXI?109, targets connective tissue growth factor (CTGF) to reduce dermal scarring (fibrosis), entered into human clinical trials in June 2012.  For more information, please visit

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, including future expectations regarding our NASDAQ listing, planned and future development of RXi Pharmaceuticals Corporation's products and technologies. Forward-looking statements about expectations and development plans of RXi's products involve significant risks, and uncertainties: risks that NASDAQ may determine that we do not meet their initial listing criteria, that if the listing is approved it will not have the intended effects of improving access to certain investors, financing flexibility and liquidity; risks that RXi may not be able to successfully develop its candidates, or that development of RNAi-based therapeutics may be delayed or not proceed as planned, or that we may not develop any RNAi-based product; risks that the development process for our product candidates may be delayed, risks related to development and commercialization of products by our competitors, risks related to our ability to control timing and terms of collaborations with third parties, and the possibility that other companies or organizations may assert patent rights preventing us from developing our products. Actual results may differ from those contemplated by these forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.
More RXII Coverage
What RXi Pharmaceuticals' Move to the Russell Microcap Index Means
RXi Pharmaceuticals Appoints Leading Ophthalmology Researcher to Scientific Advisory Board
RXi Pharma Centralizes Employee Base in New Facility
RXi Pharma Advances sd-rxRNA Platform with Key Patent
RXi Looks to Raise Awareness at Jefferies 2014 Global Healthcare Conference
RXi Pharmaceuticals Secures Key Patent on its sd-rxRNA® Technology
RXi Pharmaceuticals Begins Phase 2a Study for Keloid Recurrence
RXi Pharmaceuticals to Expand Awareness at ARVO 2014 Annual Meeting
RXi Pharmaceuticals Secures Key Patent Protecting its Self-Delivering Technology
RXi Pharmaceuticals to Reach New Investors at Wall Street Analyst Forum
RXi Pharmaceuticals Moves Up to the NASDAQ Stock Exchange
RXi Pharmaceuticals Looks to Reach New Investors at BIO CEO Conference
RXI Pharmaceuticals Could Benefit from Biotech Industry Dynamics
NIH Data Sharing Projects Could Accelerate RNAi Field
RXi Pharmaceuticals Expands Investor Awareness at Biotech Showcase 2014